  Pharmacotherapy for percutaneous coronary interventions is essential to optimize the balance<symptom> between thrombosis and bleeding. Currently , choices abound for the selection of antiplatelet and anticoagulation therapies during percutaneous intervention ( PCI). This review article discusses the mechanisms , pharmacokinetics/dynamics , and clinical data behind the various pharmacotherapies including; aspirin , thienopyridines , glycoprotein IIb/IIIa inhibitors , vorapaxar , heparin , direct thrombin inhibitors , and factor Xa inhibitors.